MCID: MLG077
MIFTS: 59

Malignant Peripheral Nerve Sheath Tumor

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Malignant Peripheral Nerve Sheath Tumor

MalaCards integrated aliases for Malignant Peripheral Nerve Sheath Tumor:

Name: Malignant Peripheral Nerve Sheath Tumor 12 49 55 14 69
Malignant Neurilemmoma 49 55 51
Neurofibrosarcoma 49 55 69
Mpnst 49 55 51
Malignant Neurofibroma 49 55
Malignant Schwannoma 49 55
Neurogenic Sarcoma 49 55
Malignant Neoplasm of the Peripheral Nerve Sheath 12
Malignant Peripheral Nerve Sheath Tumor [dup] 12
Malignant Peripheral Nerve Sheath Tumors 51

Characteristics:

Orphanet epidemiological data:

55
malignant peripheral nerve sheath tumor
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly,Infancy; Age of death: adolescent,adult,early childhood,elderly,infantile,late childhood,young Adult;

Classifications:

Orphanet: 55  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:5940
MeSH 41 D009442
NCIt 46 C3798
Orphanet 55 ORPHA3148
UMLS via Orphanet 70 C0751690 C0206729
ICD10 via Orphanet 33 C47.9
UMLS 69 C0751690

Summaries for Malignant Peripheral Nerve Sheath Tumor

NIH Rare Diseases : 49 A malignant peripheral nerve sheath tumor (MPNST) is a tumor that develops in the protective lining that covers nerves. The first symptom of MPNST is often a lump or mass that increases in size, sometimes causing pain or a tingling sensation. MPNST is considered an aggressive tumor because there is up to a 65% chance of the tumor regrowing after surgery (a recurrence), and approximately 40% chance of spreading to distant parts of the body (a metastasis), most commonly to the lung. Treatment of MPNST begins with surgery to remove as much of the tumor as possible. Radiation therapy may be used to decrease the chance of a recurrence. Chemotherapy might be used if the whole tumor cannot be removed during surgery, or to treat a metastasis. MPNSTs are quite rare, occurring in 0.001% of the general population.  Approximately 25-50% of MPNSTs are associated with a genetic condition known as neurofibromatosis type 1. Last updated: 8/18/2016

MalaCards based summary : Malignant Peripheral Nerve Sheath Tumor, also known as malignant neurilemmoma, is related to epithelioid malignant peripheral nerve sheath tumor and malignant triton tumor. An important gene associated with Malignant Peripheral Nerve Sheath Tumor is MXI1 (MAX Interactor 1, Dimerization Protein), and among its related pathways/superpathways are ERK Signaling and Cytokine Signaling in Immune system. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and kidney, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Malignant Peripheral Nerve Sheath Tumor

Diseases related to Malignant Peripheral Nerve Sheath Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 epithelioid malignant peripheral nerve sheath tumor 34.4 MUC1 NF1 S100B SMARCB1
2 malignant triton tumor 34.0 NF1 S100B
3 neurofibrosarcoma 33.7 MXI1 NF1 NF2
4 neurofibromatosis, type iv, of riccardi 31.8 KIT NF1 NF2 PDGFRA S100B
5 neurofibromatosis, type i 31.2 KIT NF1 PDGFRA
6 sarcoma, synovial 31.0 KIT MUC1 VIM
7 perineurioma 30.9 KIT MUC1 S100B VIM
8 angiosarcoma 30.8 KIT MUC1 TP53 VIM
9 neurofibroma 30.8 CDKN2A KIT MUC1 NF1 NF2 PDGFRA
10 melanoma 30.7 CDK4 CDKN2A KIT PDGFRA S100B TP53
11 liposarcoma 30.7 CDK4 CDKN2A TP53 VIM
12 malignant spindle cell melanoma 30.7 KIT NF1 SOX10
13 monophasic synovial sarcoma 30.5 MUC1 S100B VIM
14 peritoneal mesothelioma 30.5 CDKN2A EGFR MUC1 NF2
15 schwannomatosis 1 30.5 NF2 SMARCB1
16 adenocarcinoma 30.5 CDKN2A EGFR KIT MUC1 TP53
17 neuroma 30.5 NF2 S100B SMARCB1
18 dedifferentiated liposarcoma 30.4 ACTC1 CDK4 CDKN2A TP53
19 glioma 30.3 CDK4 CDKN2A EGFR PDGFRA TP53
20 hemangiopericytoma, malignant 30.3 ACTC1 MUC1 S100B VIM
21 desmoplastic small round cell tumor 30.3 ACTC1 MUC1 S100B VIM
22 cellular schwannoma 30.1 CDKN2A NF1 NF2 S100A1 S100B SOX10
23 neurilemmoma 30.0 KIT NF1 NF2 PDGFRA S100B SMARCB1
24 ewing sarcoma 29.5 CDKN2A EGFR KIT PDGFRA S100A1 S100B
25 gastrointestinal stromal tumor 29.5 ACTC1 CDKN2A KIT NF1 PDGFRA S100A1
26 malignant peripheral nerve sheath tumor with perineurial differentiation 12.5
27 childhood malignant schwannoma 12.0
28 adult malignant schwannoma 12.0
29 malignant glandular tumor of peripheral nerve sheath 11.6
30 melanocytic psammomatous mpnst 11.3
31 malignant melanocytic neoplasm of the peripheral nerve sheath 11.3
32 chromosome 17q11.2 deletion syndrome, 1.4-mb 11.2
33 gliofibroma 10.7 NF1 TP53
34 neurofibromatosis, familial spinal 10.7 NF1 NF2
35 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
36 brain ependymoma 10.7 EGFR TP53
37 squamous cell carcinoma of the larynx 10.6 CDKN2A EGFR TP53
38 localized hypertrophic neuropathy 10.6 MUC1 S100B
39 sclerosing perineurioma 10.6 MUC1 S100B
40 oropharynx cancer 10.6 CDKN2A EGFR TP53
41 ring chromosome 7 10.6 CDK4 TP53
42 basaloid squamous cell carcinoma 10.6 CDKN2A EGFR TP53
43 juvenile pilocytic astrocytoma 10.6 CDKN2A NF1 TP53
44 microglandular adenosis 10.6 EGFR S100B TP53
45 cervical adenosquamous carcinoma 10.6 CDKN2A EGFR PDGFRA
46 vulva cancer 10.6 CDKN2A EGFR TP53
47 cerebral convexity meningioma 10.6 NF2 TP53
48 squamous cell carcinoma of the oropharynx 10.6 CDKN2A TP53
49 pre-malignant neoplasm 10.6 CDKN2A EGFR TP53
50 plexiform schwannoma 10.6 KIT NF1 NF2

Graphical network of the top 20 diseases related to Malignant Peripheral Nerve Sheath Tumor:



Diseases related to Malignant Peripheral Nerve Sheath Tumor

Symptoms & Phenotypes for Malignant Peripheral Nerve Sheath Tumor

GenomeRNAi Phenotypes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

25 (show all 45)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.13 EGFR
2 Decreased viability GR00173-A 10.13 PDGFRA
3 Decreased viability GR00221-A-1 10.13 PDGFRA EGFR SMARCB1 KIT NF1 CDKN2A
4 Decreased viability GR00221-A-2 10.13 SMARCB1 NF1
5 Decreased viability GR00221-A-3 10.13 SMARCB1 PDGFRA CDKN2A
6 Decreased viability GR00221-A-4 10.13 PDGFRA EGFR NF1 CDKN2A
7 Decreased viability GR00301-A 10.13 KIT
8 Decreased viability GR00381-A-1 10.13 SMARCB1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.02 S100B SMARCB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.02 KIT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.02 SOX10
12 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.02 VIM
13 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.02 SMARCB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.02 SOX10 CDK4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.02 EGFR
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.02 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.02 SMARCB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.02 VIM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.02 KIT
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.02 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.02 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.02 VIM SMARCB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.02 VIM SOX10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.02 VIM
25 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.02 VIM EGFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.02 SMARCB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.02 EGFR CDK4
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.02 EGFR
29 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.02 VIM
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.02 VIM KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.02 SOX10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.02 KIT CDK4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.02 EGFR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.02 CDK4
35 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.02 SOX10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.02 VIM S100B
37 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.02 SOX10
38 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.02 SOX10
39 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.02 SOX10
40 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.02 SMARCB1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.02 VIM SOX10 EGFR S100B SMARCB1 KIT
42 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.02 KIT
43 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.02 KIT
44 Decreased cell migration GR00055-A-1 9.73 VIM NF2 EGFR MUC1 NF1 CDK4
45 Increased proliferation GR00094-A 9.13 TP53 SMARCB1 NF2

MGI Mouse Phenotypes related to Malignant Peripheral Nerve Sheath Tumor:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 SOX10 VIM TP53 MXI1 KIT PDGFRA
2 behavior/neurological MP:0005386 10.44 SOX10 VIM TP53 KIT PDGFRA NF2
3 cardiovascular system MP:0005385 10.43 VIM TP53 HTRA1 KIT PDGFRA NF1
4 cellular MP:0005384 10.42 SOX10 VIM TP53 MXI1 EGFR KIT
5 growth/size/body region MP:0005378 10.39 TP53 SOX10 EGFR KIT HTRA1 NF1
6 embryo MP:0005380 10.37 SOX10 VIM TP53 KIT PDGFRA NF2
7 mortality/aging MP:0010768 10.34 TP53 SOX10 VIM EGFR KIT MXI1
8 endocrine/exocrine gland MP:0005379 10.32 SOX10 TP53 MXI1 EGFR KIT PDGFRA
9 immune system MP:0005387 10.31 TP53 VIM EGFR KIT MXI1 NF1
10 digestive/alimentary MP:0005381 10.3 SOX10 TP53 KIT EGFR PDGFRA NF1
11 hematopoietic system MP:0005397 10.3 TP53 VIM EGFR KIT MXI1 NF1
12 muscle MP:0005369 10.26 VIM TP53 KIT PDGFRA NF1 S100A1
13 integument MP:0010771 10.22 SOX10 TP53 EGFR KIT NF1 PDGFRA
14 nervous system MP:0003631 10.21 TP53 SOX10 VIM EGFR KIT NF1
15 neoplasm MP:0002006 10.2 TP53 MXI1 KIT NF1 PDGFRA NF2
16 liver/biliary system MP:0005370 10.16 TP53 EGFR KIT NF1 NF2 SH3PXD2A
17 craniofacial MP:0005382 10.15 TP53 EGFR KIT NF2 NF1 PDGFRA
18 normal MP:0002873 10.1 TP53 SOX10 KIT EGFR NF1 PDGFRA
19 hearing/vestibular/ear MP:0005377 10.04 TP53 EGFR KIT NF2 NF1 SH3PXD2A
20 reproductive system MP:0005389 10 VIM TP53 MXI1 KIT EGFR PDGFRA
21 pigmentation MP:0001186 9.97 SOX10 TP53 KIT PDGFRA NF1 CDK4
22 renal/urinary system MP:0005367 9.97 TP53 MXI1 EGFR KIT NF1 PDGFRA
23 respiratory system MP:0005388 9.9 VIM TP53 KIT PDGFRA NF2 NF1
24 skeleton MP:0005390 9.61 TP53 EGFR KIT HTRA1 NF2 NF1
25 vision/eye MP:0005391 9.36 VIM TP53 HTRA1 KIT EGFR NF2

Drugs & Therapeutics for Malignant Peripheral Nerve Sheath Tumor

Drugs for Malignant Peripheral Nerve Sheath Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
15
Cyproheptadine Approved Phase 3 129-03-3 2913
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
18 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
19 Alkylating Agents Phase 3,Phase 2,Phase 1
20 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
23 Nucleic Acid Synthesis Inhibitors Phase 3
24 Imatinib Mesylate Phase 2, Phase 3,Phase 1 123596
25 Anti-Infective Agents Phase 3,Phase 1,Phase 2
26 Etoposide phosphate Phase 3,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
28 Antimitotic Agents Phase 3,Phase 2,Phase 1
29 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
31 Antirheumatic Agents Phase 3,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35
Histamine Phosphate Phase 3 51-74-1 65513
36
Serotonin Phase 3 50-67-9 5202
37 Serotonin Agents Phase 3
38 Serotonin Antagonists Phase 3
39 Gastrointestinal Agents Phase 3
40 Neurotransmitter Agents Phase 3
41 Histamine Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43 Dermatologic Agents Phase 3
44 Anti-Allergic Agents Phase 3
45 Antipruritics Phase 3
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
49
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 72)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
18 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
19 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
20 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
21 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
22 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
23 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
24 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
25 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
26 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
27 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
28 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
29 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
30 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
31 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
32 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
33 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
34 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
35 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
36 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
37 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
38 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
39 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
40 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
41 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
42 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
43 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
44 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
45 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
46 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
47 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
48 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
49 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2 temsirolimus
50 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib

Search NIH Clinical Center for Malignant Peripheral Nerve Sheath Tumor

Genetic Tests for Malignant Peripheral Nerve Sheath Tumor

Anatomical Context for Malignant Peripheral Nerve Sheath Tumor

MalaCards organs/tissues related to Malignant Peripheral Nerve Sheath Tumor:

38
Lung, Bone, Kidney, Testis, Cervix, Prostate, Liver

Publications for Malignant Peripheral Nerve Sheath Tumor

Articles related to Malignant Peripheral Nerve Sheath Tumor:

(show top 50) (show all 590)
# Title Authors Year
1
Malignant peripheral nerve sheath tumor: The need to get it right first time around. ( 29115724 )
2018
2
Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives. ( 29220302 )
2018
3
Atypical presentation of a primary cardiac malignant peripheral nerve sheath tumor. ( 29318408 )
2018
4
Malignant peripheral nerve sheath tumor of the trigeminal nerve involving the middle and posterior cranial fossa. ( 29408426 )
2018
5
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
6
Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. ( 29332262 )
2018
7
Malignant Peripheral Nerve Sheath Tumor in a Patient With BAP1 Tumor Predisposition Syndrome. ( 29061454 )
2018
8
Targeted next-generation sequencing of malignant peripheral nerve sheath tumor of the pterygopalatine fossa with intracranial metastatic recurrence. ( 29369179 )
2018
9
Doxycycline potentiates antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy in malignant peripheral nerve sheath tumor cells. ( 28558025 )
2017
10
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. ( 28534510 )
2017
11
Unusual primary breast cancer - malignant peripheral nerve sheath tumor: a case report and review of the literature. ( 28622765 )
2017
12
Rexin-G(Ar), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. ( 28588778 )
2017
13
Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. ( 28752843 )
2017
14
Role of Histone H3K27 Trimethylation Loss as a Marker for Malignant Peripheral Nerve Sheath Tumor in Fine-Needle Aspiration and Small Biopsy Specimens. ( 28898989 )
2017
15
Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors. ( 28813519 )
2017
16
Malignant Peripheral Nerve Sheath Tumor of the Inguinum and Angiosarcoma of the Scalp in a Child with Neurofibromatosis Type 1. ( 29138703 )
2017
17
Malignant Triton Tumor (Malignant Peripheral Nerve Sheath Tumor With Rhabdomyoblastic Differentiation) Occurring in a Vascularized Free Flap Reconstruction Graft. ( 28387148 )
2017
18
Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computed Tomography Masquerading as a Case of Sporadic Malignant Peripheral Nerve Sheath Tumor of Lower Extremity Presenting as Massive Lower Limb Edema. ( 29033684 )
2017
19
NF1(+/-) Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. ( 28646022 )
2017
20
Metastatic Epithelioid Malignant Peripheral Nerve Sheath Tumor in a Known Case of Neurofibromatosis-1, Cytomorphological Appearance, and Critical Analysis of Immunohistochemistry. ( 29200699 )
2017
21
Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016. ( 29285213 )
2017
22
Malignant peripheral nerve sheath tumor of the vagus nerve: an uncommon cause of progressive dyspnea. ( 29307938 )
2017
23
Primary Intraosseous Malignant Peripheral Nerve Sheath Tumor of Metacarpal Bones of the Hand in a Patient Without Neurofibromatosis 1: Report of a Rare Case. ( 28900340 )
2017
24
Successful treatment with doxorubicin and ifosfamide for mediastinal malignant peripheral nerve sheath tumor with loss of H3K27me3 expression. ( 28876532 )
2017
25
Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. ( 27477693 )
2017
26
Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. ( 28551330 )
2017
27
Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. ( 27706810 )
2017
28
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors. ( 28124441 )
2017
29
Hypoxia-inducible factor 1 alpha is a poor prognostic factor and potential therapeutic target in malignant peripheral nerve sheath tumor. ( 28558056 )
2017
30
Malignant peripheral nerve sheath tumor in children: A single-institute retrospective analysis. ( 29286874 )
2017
31
Malignant Peripheral Nerve Sheath Tumor of the Femur: A Rare Diagnosis Supported by Complete Immunohistochemical Loss of H3K27me3. ( 28508686 )
2017
32
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. ( 27875628 )
2017
33
The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells. ( 28502478 )
2017
34
CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. ( 28549031 )
2017
35
Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1. ( 28658406 )
2017
36
Acute hydrocephalus due to a primary malignant peripheral nerve sheath tumor of the cervicothoracic junction: A case report and review of the literature. ( 28502561 )
2017
37
Radiation-Induced Glandular Malignant Peripheral Nerve Sheath Tumor. ( 28530162 )
2017
38
Spindle cell type malignant peripheral nerve sheath tumor arising in benign schwannoma with multiple intraosseous spinal metastasis: A case report. ( 28505957 )
2017
39
Metastatic angiosarcoma arising in malignant peripheral nerve sheath tumor in a young patient with neurofibromatosis type 1. ( 28548697 )
2017
40
Malignant peripheral nerve sheath tumor coexisting with congenital melanocytic nevus in an elderly man. ( 26897251 )
2016
41
Malignant Peripheral Nerve Sheath Tumor of the Infraorbital Nerve. ( 27162577 )
2016
42
Malignant Peripheral Nerve Sheath Tumor of Prostate: A Rare Case Report and Literature Review. ( 27872789 )
2016
43
Synchronous Malignant Peripheral Nerve Sheath Tumor and Adenocarcinoma of the Prostate: Case Report and Literature Review. ( 27872787 )
2016
44
Malignant Peripheral Nerve Sheath Tumor of the Liver. ( 26831017 )
2016
45
Fine-needle aspiration cytology of epithelioid malignant peripheral nerve sheath tumor: A case report and review of the literature. ( 26646298 )
2016
46
Intraneural ganglion cyst of the ulnar nerve at the elbow masquerading as a malignant peripheral nerve sheath tumor. ( 27593718 )
2016
47
Low-grade malignant peripheral nerve sheath tumor: a report of the first case in the breast and literature review. ( 26899712 )
2016
48
Breast metastases from a malignant peripheral nerve sheath tumor of the kidney: An unusual presentation. ( 27453670 )
2016
49
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. ( 27588404 )
2016
50
Palliative Epineurotomy for Focal Radial Malignant Peripheral Nerve Sheath Tumor in a Dog. ( 27487351 )
2016

Variations for Malignant Peripheral Nerve Sheath Tumor

ClinVar genetic disease variations for Malignant Peripheral Nerve Sheath Tumor:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh37 Chromosome 10, 111988034: 111988034

Copy number variations for Malignant Peripheral Nerve Sheath Tumor from CNVD:

7 (show all 45)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17387 1 142600000 147000000 Gain Malignant peripheral nerve sheath tumor
2 22132 1 165500000 170900000 Gain Malignant peripheral nerve sheath tumor
3 23047 1 170900000 176000000 Gain Malignant peripheral nerve sheath tumor
4 49109 11 102900000 112500000 Loss Malignant peripheral nerve sheath tumor
5 49995 11 112500000 121200000 Loss Malignant peripheral nerve sheath tumor
6 53584 11 31000000 36400000 Loss Malignant peripheral nerve sheath tumor
7 61507 12 1 3100000 Gain FOXM1 Malignant peripheral nerve sheath tumor
8 65742 12 21200000 26300000 Amplification SOX5 Malignant peripheral nerve sheath tumor
9 66816 12 3300000 10100000 Gain Malignant peripheral nerve sheath tumor
10 67235 12 38200000 49100000 Gain Malignant peripheral nerve sheath tumor
11 69080 12 5300000 10000000 Gain NOL1 Malignant peripheral nerve sheath tumor
12 69882 12 56428269 56432431 Gain CDK4 Malignant peripheral nerve sheath tumor
13 69960 12 56600000 71500000 Gain Malignant peripheral nerve sheath tumor
14 71535 12 71500000 86700000 Gain Malignant peripheral nerve sheath tumor
15 73254 12 92600000 109000000 Gain Malignant peripheral nerve sheath tumor
16 73259 12 92600000 96200000 Gain Malignant peripheral nerve sheath tumor
17 75380 13 19500000 25500000 Gain Malignant peripheral nerve sheath tumor
18 76637 13 34000000 55300000 Gain Malignant peripheral nerve sheath tumor
19 79536 13 73300000 77200000 Gain Malignant peripheral nerve sheath tumor
20 85488 14 47200000 67900000 Loss Malignant peripheral nerve sheath tumor
21 87451 14 73800000 107349540 Gain Malignant peripheral nerve sheath tumor
22 97234 16 1 10500000 Gain Malignant peripheral nerve sheath tumor
23 102841 16 57400000 90354753 Gain Malignant peripheral nerve sheath tumor
24 105377 16 7900000 14800000 Gain Malignant peripheral nerve sheath tumor
25 115613 17 58300000 81195210 Gain Malignant peripheral nerve sheath tumor
26 124065 19 1 13900000 Gain Malignant peripheral nerve sheath tumor
27 147242 2 61300000 68600000 Gain Malignant peripheral nerve sheath tumor
28 150135 2 96800000 114400000 Gain Malignant peripheral nerve sheath tumor
29 163892 22 32200000 44200000 Gain Malignant peripheral nerve sheath tumor
30 172609 3 184500000 198022430 Gain Malignant peripheral nerve sheath tumor
31 174546 3 2800000 16400000 Gain Malignant peripheral nerve sheath tumor
32 175421 3 39400000 54400000 Gain Malignant peripheral nerve sheath tumor
33 196162 5 159900000 180915260 Gain Malignant peripheral nerve sheath tumor
34 198008 5 18400000 23300000 Gain Malignant peripheral nerve sheath tumor
35 209673 6 27000000 57000000 Gain Malignant peripheral nerve sheath tumor
36 213890 6 52900000 70000000 Gain Malignant peripheral nerve sheath tumor
37 220382 7 13800000 43300000 Gain Malignant peripheral nerve sheath tumor
38 227906 7 72200000 86400000 Gain Malignant peripheral nerve sheath tumor
39 240607 8 52600000 146364022 Gain Malignant peripheral nerve sheath tumor
40 241476 8 6200000 36500000 Gain Malignant peripheral nerve sheath tumor
41 244863 9 1 14200000 Gain Malignant peripheral nerve sheath tumor
42 247559 9 130300000 135900000 Gain Malignant peripheral nerve sheath tumor
43 249423 9 14200000 28000000 Loss Malignant peripheral nerve sheath tumor
44 255080 9 72339785 73251640 Dramatically overexp ressed,genomicallyamplified TRPM3 Malignant peripheral nerve sheath tumor
45 255774 9 84100000 102600000 Gain Malignant peripheral nerve sheath tumor

Expression for Malignant Peripheral Nerve Sheath Tumor

Search GEO for disease gene expression data for Malignant Peripheral Nerve Sheath Tumor.

Pathways for Malignant Peripheral Nerve Sheath Tumor

Pathways related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 CDK4 CDKN2A EGFR KIT MUC1 NF1
2
Show member pathways
13.28 EGFR KIT MUC1 NF1 NRG1 PDGFRA
3 12.72 CDK4 CDKN2A EGFR KIT PDGFRA TP53
4 12.68 EGFR KIT NF1 PDGFRA TP53
5
Show member pathways
12.64 EGFR KIT NRG1 PDGFRA TP53
6
Show member pathways
12.6 CDK4 CDKN2A EGFR KIT SMARCB1 TP53
7
Show member pathways
12.44 CDK4 CDKN2A EGFR KIT NF1 NRG1
8 12.42 CDKN2A EGFR PDGFRA TP53 VIM
9
Show member pathways
12.41 EGFR MUC1 NRG1 TP53
10 12.4 CDK4 CDKN2A TOP2A TP53 VIM
11 12.34 CDK4 CDKN2A PDGFRA TP53
12 12.08 CDK4 EGFR NF1 TP53
13
Show member pathways
12.07 CDK4 CDKN2A EGFR TP53
14 12.04 EGFR KIT NRG1 PDGFRA
15
Show member pathways
11.98 CDK4 EGFR NF1 NRG1
16 11.87 CDK4 EGFR TP53 VIM
17 11.75 CDK4 TOP2A TP53
18 11.65 CDKN2A TOP2A TP53
19 11.6 PDGFRA S100B SOX10 VIM
20 11.53 CDK4 CDKN2A EGFR TP53
21 11.51 CDK4 NF1 PDGFRA
22 11.44 EGFR KIT PDGFRA TP53
23 11.28 ACTC1 KIT NRG1 PDGFRA
24 11.21 CDK4 CDKN2A EGFR NF1 NF2 PDGFRA
25 11.2 EGFR TOP2A TP53
26 11.16 CDK4 CDKN2A TP53
27 11.16 CDKN2A EGFR PDGFRA TP53

GO Terms for Malignant Peripheral Nerve Sheath Tumor

Cellular components related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.7 CDK4 EGFR PDGFRA S100A1 SMARCB1 TOP2A
2 cytoplasm GO:0005737 9.58 ACTC1 CDK4 CDKN2A EGFR HTRA1 KIT
3 nucleolus GO:0005730 9.56 CDK4 CDKN2A MXI1 NF1 NF2 SMARCB1
4 cell body GO:0044297 9.5 ACTC1 NF2 NRG1
5 nucleus GO:0005634 10.13 CDK4 CDKN2A EGFR MUC1 MXI1 NF1

Biological processes related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 CDK4 EGFR KIT NRG1 PDGFRA S100B
2 MAPK cascade GO:0000165 9.88 EGFR KIT NF1 NRG1 PDGFRA
3 negative regulation of cell proliferation GO:0008285 9.88 CDKN2A MXI1 NF1 NF2 SMARCB1 TP53
4 peptidyl-tyrosine phosphorylation GO:0018108 9.86 EGFR KIT NRG1 PDGFRA
5 positive regulation of protein kinase B signaling GO:0051897 9.83 EGFR KIT NRG1 PDGFRA
6 regulation of cell proliferation GO:0042127 9.83 CDK4 EGFR KIT NF1 NF2
7 Ras protein signal transduction GO:0007265 9.77 CDKN2A NF1 TP53
8 cellular response to drug GO:0035690 9.76 EGFR SOX10 TP53
9 phosphatidylinositol phosphorylation GO:0046854 9.76 EGFR KIT NRG1 PDGFRA
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 KIT NRG1 PDGFRA
11 positive regulation of apoptotic process GO:0043065 9.73 CDK4 CDKN2A NF1 S100B TOP2A TP53
12 positive regulation of fibroblast proliferation GO:0048146 9.72 CDK4 EGFR PDGFRA
13 cellular response to reactive oxygen species GO:0034614 9.67 EGFR PDGFRA TP53
14 replicative senescence GO:0090399 9.62 CDKN2A TP53
15 cardiac myofibril assembly GO:0055003 9.62 ACTC1 PDGFRA
16 tongue development GO:0043586 9.61 EGFR KIT
17 somatic stem cell division GO:0048103 9.61 CDKN2A KIT
18 positive regulation of phospholipase C activity GO:0010863 9.59 KIT PDGFRA
19 positive regulation of histone H4 acetylation GO:0090240 9.54 MUC1 SMARCB1
20 peripheral nervous system development GO:0007422 9.54 NF1 NRG1 SOX10
21 negative regulation of cell-matrix adhesion GO:0001953 9.5 CDKN2A NF1 NF2
22 positive regulation of gene expression GO:0010628 9.5 ACTC1 CDKN2A KIT NRG1 SOX10 TP53
23 positive regulation of myelination GO:0031643 9.33 NRG1 S100B SOX10
24 wound healing GO:0042060 9.02 EGFR NF1 NRG1 PDGFRA TP53
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 CDKN2A EGFR NRG1 SMARCB1 SOX10 TOP2A

Molecular functions related to Malignant Peripheral Nerve Sheath Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 EGFR HTRA1 S100A1 S100B SOX10 TP53
2 p53 binding GO:0002039 9.61 MUC1 SMARCB1 TP53
3 protein tyrosine kinase activity GO:0004713 9.56 EGFR KIT NRG1 PDGFRA
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.5 EGFR KIT PDGFRA
5 S100 protein binding GO:0044548 9.46 S100A1 S100B
6 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR KIT
7 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.26 EGFR KIT NRG1 PDGFRA
8 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.92 EGFR KIT NRG1 PDGFRA
9 protein binding GO:0005515 10.11 CDK4 CDKN2A EGFR HTRA1 KIT MUC1

Sources for Malignant Peripheral Nerve Sheath Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....